Wanted pages

From Glioblastoma Treatments
Jump to navigationJump to search

List of non-existing pages with the most links to them, excluding pages which only have redirects linking to them. For a list of non-existent pages that have redirects linking to them, see the list of broken redirects.

Showing below up to 50 results in range #101 to #150.

View ( | ) (20 | 50 | 100 | 250 | 500)

  1. Not specifically documented; focus on overall survival improvements‏‎ (2 links)
  2. Not specified; however, survival six months after recurrence was used as a primary measure in comparative studies with Avastin‏‎ (2 links)
  3. Not specified; primary focus has been on edema reduction and potentially improved quality of life‏‎ (2 links)
  4. Not specified; studies have focused on steroid requirements and edema control‏‎ (2 links)
  5. Not specified in the provided context‏‎ (2 links)
  6. Not specified in the provided information‏‎ (2 links)
  7. Optune (Optune Gio® for newer version)‏‎ (2 links)
  8. Over-the-Counter Drugs and Supplements‏‎ (2 links)
  9. PSK (Polysaccharide Krestin) and other polysaccharides‏‎ (2 links)
  10. Pending further clinical trials‏‎ (2 links)
  11. Pending further clinical trials and data‏‎ (2 links)
  12. Pending review of recent clinical trials and comparative studies‏‎ (2 links)
  13. Perillyl Alcohol/Limonene‏‎ (2 links)
  14. Phase 2 clinical trial in 2021 indicated for glioblastoma‏‎ (2 links)
  15. Phase 3‏‎ (2 links)
  16. Phase II trial showed a significant improvement in PFS, particularly for HLA-A2 positive patients with methylated MGMT, showing a median PFS of 24.1 months vs. 8.5 months in the control group.‏‎ (2 links)
  17. Post-hoc analysis with at least six months of Valcyte use: median survival of 24 months, 4-year survival of 27%‏‎ (2 links)
  18. Preclinical studies‏‎ (2 links)
  19. Preclinical studies and early clinical trials‏‎ (2 links)
  20. Radiation dermatitis, temporary alopecia, radiation otitis, radiation necrosis (more prevalent in PBT group)‏‎ (2 links)
  21. Ranges from 26 to 44% with different schedules; 61% PFS-6 with the best results obtained using a specific dosing schedule‏‎ (2 links)
  22. Recent meta-analyses suggest potential for improving cancer treatment outcomes‏‎ (2 links)
  23. SL-701 (Immunotherapy Vaccine)‏‎ (2 links)
  24. Shows a clinically meaningful extension of survival in both newly diagnosed and recurrent GBM patients. Offers fresh hope by potentially improving outcomes in a challenging treatment landscape.‏‎ (2 links)
  25. Shows promise based on significant improvements in overall survival and disease-free survival in high-risk AML patients; ongoing research needed to fully establish efficacy in other cancers‏‎ (2 links)
  26. Some studies report mean progression-free survival up to 17.2 months, compared to 4-10 months for other treatments‏‎ (2 links)
  27. Standard progression statistics for GBM.‏‎ (2 links)
  28. Standard radiation therapy PFS rates are lower compared to PBT‏‎ (2 links)
  29. Standard treatments for GBM typically result in a median overall survival of 14-17 months‏‎ (2 links)
  30. Standard treatments offer a median progression-free survival of about 6.9 months.‏‎ (2 links)
  31. TMZ‏‎ (2 links)
  32. The vaccine shows promise, especially in extending progression-free survival in newly diagnosed GBM. It offers a novel approach by leveraging the patient's immune system, potentially improving outcomes in a disease with few effective treatments.‏‎ (2 links)
  33. This vaccine represents a promising strategy by targeting CMV antigens present in GBM cells, potentially extending survival significantly beyond standard treatments. Initial results suggest substantial benefits for certain patient groups.‏‎ (2 links)
  34. Typically, tumors recur within 6 months of standard treatment.‏‎ (2 links)
  35. Under investigation; early results promising, especially in combination therapies‏‎ (2 links)
  36. Valganciclovir (Valcyte)‏‎ (2 links)
  37. Variable across studies‏‎ (2 links)
  38. Varies; can include fatigue, headache, localized reactions at infusion site‏‎ (2 links)
  39. Varies; earlier phases showed median overall survival up to 38 months in phase I trial participants.‏‎ (2 links)
  40. Varies; one GBM patient had a significant tumor shrinkage, others showed extended progression-free survival, including one patient surviving 87 months post-diagnosis‏‎ (2 links)
  41. Wilms Tumor Peptide Vaccine‏‎ (2 links)
  42. Property:Has Usefulness Explanation‏‎ (2 links)
  43. 17.8 months for newly diagnosed GBM, possibly the longest PFS seen in a phase II trial for GBM‏‎ (1 link)
  44. 4 months (control group in EF-14 Trial)‏‎ (1 link)
  45. 7.1 months (Optune arm in EF-14 Trial); 6.7 months from diagnosis in updated analysis‏‎ (1 link)
  46. 7.5 months in metastatic breast cancer patients receiving only chemotherapy‏‎ (1 link)
  47. 9.5 months with 100 mg Nexium; 10.9 months with 80 mg Nexium‏‎ (1 link)
  48. AVAglio trial: 10.6 months; RTOG trial: 10 months‏‎ (1 link)
  49. AVAglio trial: 16.7 months; RTOG trial: 16.1 months‏‎ (1 link)
  50. AVAglio trial: 6.2 months; RTOG trial: 7.3 months‏‎ (1 link)

View ( | ) (20 | 50 | 100 | 250 | 500)

Retrieved from "http://glioblastomatreatments.wiki:80/index.php?title=Special:WantedPages"